SELLAS Life Sciences (SLS) EBT Margin (2012 - 2022)
SELLAS Life Sciences (SLS) posted quarterly EBT Margin of 1683.5% for Q1 2022, down 164236.0% year-over-year from N/an in Q1 2021, and down 602.54% quarter-over-quarter from 239.63% in Q2 2021.
SELLAS Life Sciences (SLS) EBT Margin (2012 - 2022) Analysis & Trends
SELLAS Life Sciences (SLS) has reported EBT Margin for 7 consecutive years, with 1683.5% the latest figure, recorded in Q1 2022.
- In Q1 2022, EBT Margin fell 164236.0% year-over-year to 1683.5%; the TTM figure through Dec 2022 stood at 4245.0% (down 390692.0% YoY), while the FY2022 annual figure was 4130.1%, down 385463.0% from the prior year.
- EBT Margin eased to 1683.5% in Q1 2022 per SLS's latest filing, from 239.63% in the prior quarter.
- Across five years, EBT Margin topped out at 41.14% in Q1 2021 and bottomed at 1683.5% in Q1 2022.
- Historically, EBT Margin has averaged 547.11% across 3 years, with a median of 231.89% in 2020.
- On a YoY basis, EBT Margin climbed as much as 164236 bps in 2022 and fell as far as 164236 bps in 2022.
- SELLAS Life Sciences' EBT Margin stood at 224.16% in 2020, then slipped by 7 bps to 239.63% in 2021, then sank by 603 bps to 1683.5% in 2022.
- Business Quant data shows SLS's EBT Margin at 1683.5% in Q1 2022, 239.63% in Q2 2021, and 41.14% in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -1,683.50% |
| Jun 30, 2021 | -239.63% |
| Mar 31, 2021 | -41.14% |
| Dec 31, 2020 | -224.16% |
| Jun 30, 2015 | -294.94% |
| Mar 31, 2015 | -341.45% |
| Dec 31, 2014 | -308.64% |
| Sep 30, 2014 | -748.02% |
| Jun 30, 2014 | -947.70% |
| Mar 31, 2014 | -716.38% |
| Dec 31, 2013 | -1,315.68% |
| Sep 30, 2013 | -501.73% |
| Jun 30, 2013 | -345.60% |
| Mar 31, 2013 | -554.76% |
| Dec 31, 2012 | 410.51% |
| Sep 30, 2012 | -535.13% |